Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMcpc1516450 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.
JAMA Oncol
June 2024
Department of Internal Medicine, Hematology, and Internal Oncology, Hospital Barmherzige Brueder, Vienna, Austria.
Importance: Studies with nivolumab, an approved therapy for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy, demonstrate improved outcomes with added high-dose ipilimumab.
Objective: To assess efficacy and safety of a tailored approach using nivolumab + ipilimumab as an immunotherapeutic boost for mUC.
Design, Setting, And Participants: In this phase 2 nonrandomized trial, patients with mUC composed 2 cohorts.
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Lancet Oncol
May 2023
Mayo Clinic Arizona, Phoenix, AZ, USA. Electronic address:
Article Synopsis
- HER2 is a critical target for treatment in metastatic colorectal cancer, leading to a study evaluating the combined effects of tucatinib and trastuzumab on patients who have not responded to chemotherapy.
- The MOUNTAINEER study analyzed patients aged 18 and older with HER2-positive, RAS wild-type colorectal cancer across various sites in five countries, first as a single-cohort and later expanding participation based on interim results.
- A total of 117 patients were enrolled, with most receiving treatment in different cohorts to assess the drug's effectiveness and safety, highlighting the ongoing nature of the research and its registration on ClinicalTrials.gov.
mutations in intellectual disability and epilepsy: A report of 2 cases and literature review.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
February 2022
Department of Pediatrics, Xiangya Hospital, Central South University; Research Center of Children Intellectual Disability of Hunan Province, Changsha 410008, China.
More than 100 genes located on the X chromosome have been found to be associated with X-linked intellectual disability (XLID) to date, and is a pathogenic gene for XLID. In addition to intellectual disability, patients with gene mutation can also have other neurological symptoms, such as epilepsy, abnormal behavior, and hypotonia, as well as abnormalities of other systems. Two children with intellectual disability and epilepsy caused by gene mutation were treated in the Department of Pediatrics, Xiangya Hospital, Central South University from March 8, 2017 to June 20, 2020.
View Article and Find Full Text PDFTreatment of Diabetic Macular Edema with Aflibercept and Micropulse Laser (DAM Study).
Clin Ophthalmol
April 2022
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Purpose: To investigate the safety and efficacy of micropulse (MP) macular laser in combination with intravitreal aflibercept for the treatment of center-involved diabetic macular edema (CI-DME).
Methods: A single-blind prospective randomized controlled pilot trial was performed. In total, 30 eyes of 30 patients with CI-DME and best corrected visual acuity (BCVA) between, and including, 20/30 and 20/400 were enrolled.
Gout is the best-known type of arthritis with a prevalence of 1%-3% in the western world (Therapeutic Advances in Musculoskeletal Disease, 6, 2014 and 131; Journal of Advanced Research, 8, 2017 and 495). Although it is well understood, there is growing evidence of the misdiagnosis of gout from other forms of arthritis. These errors lead to delay in accurate diagnosis (Journal of Advanced Research, 8, 2017 and 495).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!